Tuesday 18 June 2019 - 22:08
In Business 39 Years - Since 1980
LC Labs Product Usage Update: Rapamycin, Doxorubicin, Paclitaxel, and 33 Others -- April 17, 2019.
FREE SHIPPING TO THE U.S. AND 33 OTHER COUNTRIES! [Read more].
Search:
G-5903 GW2580, Free Base, >99%
- Size
- US $
- €
- £
- ¥
- 100 mg
- 86
- 76
- 68
- 9,300
- In stock
- 300 mg
- 207
- 184
- 165
- 22,400
- In stock
- 1 g
- 446
- 398
- 355
- 48,300
- In stock
- 5 g
- 1,725
- 1,540
- 1,376
- 186,700
- In stock
- 10 g
- 2,670
- 2,384
- 2,130
- 289,000
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 366.41
- C20H22N4O3
- [870483-87-7]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 40 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
- GW2580 is a small-molecule inhibitor of cFMS kinase; at 60 nM it inhibited human cFMS kinase completely in vitro and was inactive against 26 other kinases. GW2580 inhibited lipopolysaccharide (LPS)-induced TNF production in mice, but not LPS-induced TNF production in freshly isolated human monocytes and mouse macrophages in vitro. Also, GW2580 at 1 µM totally inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes, and prevented bone degradation in cultures of rat calvaria and rat fetal long bone in vitro. Conway, J.G., et al. "Inhibition of colony-stimulating-factor-1 signaling in vitro with the orally bioavailable cFMS kinase inhibitor GW2580." Proc. Natl. Acad. Sci. USA 102: 16078-16083 (2005).
- In an arthritic rat model, GW2580 inhibited joint connective tissue and bone destruction, and thus preserved joint integrity. Conway, J.G., et al. "Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats." J. Pharmacol. Exp. Ther. 326: 41-50 (2008).
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
